{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-000499","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.753940+00:00","generated_at":"2026-06-20T19:38:32.889264+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Genprex enters exclusive license with University of Pittsburgh for Type 2 diabetes gene therapy","bullets":["Genprex (GNPX) licensed worldwide exclusive rights to gene therapy using Pdx1 and MafA genes for Type 2 diabetes from University of Pittsburgh.","License includes milestone payments up to $4.0 million, single-digit royalties, and a low double-digit share of sublicense income.","The GPX-003 technology aims to rejuvenate beta cells to increase insulin expression; preclinical data accepted for oral presentation at ATTD 2023.","This is the third diabetes technology license from University of Pittsburgh in 2022, covering both Type 1 (GPX-002) and Type 2 diabetes programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-000499","json":"https://secwatch.observer/filing/0001437749-23-000499.json","markdown":"https://secwatch.observer/filing/0001437749-23-000499.md","text":"https://secwatch.observer/filing/0001437749-23-000499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/0001437749-23-000499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/gnpx20230103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:38:32.889264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae9b1c49d0ecc52f37af33fdb3018323bb68a636","claim":"Genprex, Inc. entered into UP License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at approximately $4,000,000 (effective 2022-12-29).","evidence_excerpt":"As consideration for the UP License Agreement, Genprex agreed to pay UP an initial license fee, annual maintenance fees, running single digit royalties, minimum annual royalties in a fixed cash amount, a low double digit percentage share of non-royalty sublicense income, and certain milestone payments up to an aggregate of approximately $4,000,000, as well as patent prosecution expenses incurred prior to and after the effective date of the UP License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/0001437749-23-000499-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"University of Pittsburgh - Of the Commonwealth System of Higher Education"},{"label":"Value","value":"approximately $4,000,000"},{"label":"Effective","value":"2022-12-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}